Our team has investigated the role of biopsies during treatment to predict response to neoadjuvant chemotherapy in breast cancer patients.
This year, the impressive ESMO 2024 congress will take place in Barcelona, where we will be on site with the following presentations.
While the difference in overall survival has not yet reached statistical significance, pertuzumab remains an important therapeutic option due to the improved invasive disease-free survival in this patient group.
Successful inclusion of the first patient in our MOMENTUM study by the St. Vincenz Hospital trial center team in Limburg.
With 18 randomised patients, we have already reached 50% of our target in just under 6 months!
